Anti-inflammatory cosmetic composition

Abstract

The present invention relates to an anti-inflammatory cosmetic composition. According to the present invention, a cosmetic composition is provided that can suppress the production of reactive nitrogen species, which are inflammation mediators involved in inducing inflammation within cells.

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority rights under Republic of Korea Patent Application No. 10-2023-0120962 dated September 12, 2023, Republic of Korea Patent Application No. 10-2024-0099305 dated July 26, 2024, and Republic of Korea Patent Application No. 10-2024-0099306 dated July 26, 2024, and all content disclosed in the literature of said Republic of Korea Patent Applications is incorporated herein by reference.

[0002] This invention relates to a cosmetic composition that exhibits anti-inflammatory effects. [Background technology]

[0003] The human body contains a group of oxidizing agents that include nitrogen atoms (N), and these are called reactive nitrogen species (RNS). While reactive nitrogen species are sometimes classified as independent species, they are generally classified as a subgroup of reactive oxygen species (ROS).

[0004] The most crucial reactive oxygen species in the human body, and the first to be produced in mitochondria, is superoxide. Superoxide is converted by enzymes into hydrogen peroxide, which has relatively weaker oxidizing power and less impact on cells. However, hydrogen peroxide can also generate hydroxyl radicals through interactions with metal ions.

[0005] The most basic of the reactive nitrogen species is nitric oxide (NO). Synthesized in the human body by NO synthase (NOS), nitric oxide is a neurotransmitter involved in blood pressure regulation and vascular reconnection, among other things. Nitric oxide is also linked to immune responses and the development of chronic inflammatory diseases such as rheumatoid arthritis. Nitric oxide reacts with oxygen and superoxide to produce nitrates (NO3). - ), nitrite (NO2 -), nitrate peroxide (ONOO - ), and also generate other reactive nitrogen species such as 3-nitrotyrosine. Thus, reactive nitrogen species are produced by the activity of normal cells and function to regulate cell proliferation and differentiation.

[0006] However, reactive nitrogen species (REs) increase in production during inflammatory processes and are important inflammatory mediators in both acute and chronic inflammation. REs play a role as intracellular signaling regulators, but when their concentration exceeds positive levels, they induce cell damage. It is known that excessive increases in REs, caused by oxidative stress on cells in environments such as infrared radiation, viral infections, and hyperglycemia, can contribute to inflammatory diseases such as cancer and diabetes.

[0007] Therefore, consumer demand for products that exhibit anti-inflammatory effects, such as preventing, treating, or improving symptoms caused by intracellular inflammation, continues to increase. [Overview of the project] [Problems that the invention aims to solve]

[0008] This invention provides an anti-inflammatory cosmetic composition.

[0009] Furthermore, the present invention provides an anti-inflammatory pharmaceutical composition. [Means for solving the problem]

[0010] According to one embodiment of the invention, an anti-inflammatory cosmetic composition is provided that contains 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0011] According to another embodiment of the invention, the use of 3-hydroxypropionic acid or its derivatives for the manufacture of anti-inflammatory cosmetics is provided.

[0012] According to still other embodiments of the invention, there is provided a method for suppressing the production of reactive nitrogen species, which are inflammatory mediators, using a cosmetic composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0013] According to still other embodiments of the invention, there is provided an anti-inflammatory composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0014] According to still other embodiments of the invention, there is provided the use of 3-hydroxypropionic acid or a derivative thereof for the manufacture of an anti-inflammatory agent.

[0015] According to still other embodiments of the invention, there is provided a method for suppressing the production of reactive nitrogen species, which are inflammatory mediators, using a pharmaceutical composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0016] Hereinafter, the anti-inflammatory cosmetic composition and the anti-inflammatory pharmaceutical composition according to the embodiments of the invention will be described in more detail.

[0017] The terms and words used in this specification and the claims should not be construed as being limited to ordinary or dictionary meanings. In accordance with the principle that the inventor can appropriately define the concept of the terms in order to explain his invention in the best way, they should be construed in a meaning and concept consistent with the technical idea of the invention.

[0018] Unless otherwise defined herein, all technical and scientific terms have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terms used in the description of the present invention are merely for the purpose of effectively describing specific examples and are not intended to limit the present invention.

[0019] Although the present invention can be modified in various ways and can have various forms, specific embodiments will be illustrated and described in detail below. However, this is not intended to limit the present invention to a specific disclosed form, and it should be understood that it includes all modifications, equivalents, or alternatives included in the above idea and technical scope.

[0020] As used herein, the singular forms also include the plural forms unless the context clearly indicates the contrary meaning.

[0021] As used herein, the meaning of "comprising" embodies a specific characteristic, region, integer, step, operation, element, and / or component, and does not exclude the existence or addition of other specific characteristics, regions, integers, steps, operations, elements, components, and / or groups.

[0022] In this specification, for example, when the temporal sequence is described by "after...", "subsequent to...", "next...", "before...", etc., as long as the expressions "immediately" or "directly" are not used, it can include non - consecutive cases.

[0023] In this specification, the "derivative" means a compound in which the structure and properties of the parent compound of an organic compound change within the limit that the introduction of a functional group, oxidation, reduction, substitution of atoms, etc. do not significantly change the structure of the parent body.

[0024] In this specification, the term "containing as an active ingredient" means that the composition according to the embodiment of the invention contains 3 - hydroxypropionic acid or its derivative in an amount sufficient to achieve an anti - inflammatory effect.

[0025] And in this specification, "anti - inflammatory" means alleviating or interrupting an inflammatory reaction or participating in and suppressing the process in which inflammation occurs.

[0026] In this specification, the term "prevention" means suppression of the occurrence of symptoms caused by reactive oxygen species. In this specification, the term "treatment" means reduction or elimination of symptoms caused by reactive oxygen species that have already occurred. And in this specification, the term "improvement" means reduction or mitigation of symptoms caused by reactive oxygen species.

[0027] As a result of our continued research, we have confirmed that 3-hydroxypropionic acid can exhibit excellent anti-inflammatory effects, such as preventing, alleviating, or improving symptoms caused by intracellular inflammation.

[0028] In particular, 3-hydroxypropionic acid suppresses the production of reactive nitrogen species, which are inflammation mediators involved in inducing inflammation within cells, thereby enabling cosmetic compositions containing 3-hydroxypropionic acid or its derivatives as active ingredients to exhibit excellent anti-inflammatory effects.

[0029] According to one embodiment of the invention, an anti-inflammatory cosmetic composition is provided that contains 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0030] The anti-inflammatory cosmetic composition contains 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Preferably, the anti-inflammatory cosmetic composition contains 3-hydroxypropionic acid as an active ingredient.

[0031] 3-hydroxypropionic acid can be used as an active ingredient if it is synthesized by chemical or biological methods.

[0032] According to one embodiment, 3-hydroxypropionic acid obtained by a biological process such as fermenting a bacterial strain capable of producing 3-hydroxypropionic acid can preferably be used as the active ingredient. The 3-hydroxypropionic acid obtained by the above method is a radioactive carbon isotope ( 14 C) May include.

[0033] Preferably, the active ingredient may have a radiocarbon isotope content of 20 pMC (percent modern carbon) or more and a bio-carbon content of 20% by weight or more, measured according to ASTM D6866-21 standard. Specifically, the active ingredient may have a radiocarbon isotope content of 20 pMC or more, or 50 pMC or more, or 90 pMC or more, or 100 pMC or more, or 90 - 110 pMC, measured according to ASTM D6866-21 standard; and the bio-carbon content may be 20% by weight or more, or 50% by weight or more, or 80% by weight or more, or 90% by weight or more, or 95% by weight or more, or 90 - 100% by weight.

[0034] The content of the radiocarbon isotope (pMC) refers to the ratio of the radiocarbon isotope ( 14 C) contained in 3-hydroxypropionic acid to the radiocarbon isotope ( 14 [[ID=Z]]C) of the modern reference material. For reference, since the effect of the nuclear test program in the 1950s continues and has not disappeared, the content of the radiocarbon isotope (pMC) may be greater than 100%.

[0035] The content of the bio-carbon indicates the content of bio-carbon relative to the total carbon content contained in 3-hydroxypropionic acid. The larger this value is, the more it can be considered as an environmentally friendly compound.

[0036] If the content of the radiocarbon isotope (pMC) and the bio-carbon content of the 3-hydroxypropionic acid are excessively low, the environmental consideration will decrease and it will not be regarded as a bio-derived substance. The radiocarbon isotope ( 14 C) is about 1 per 1×10 12 carbon atoms in the earth's atmosphere, has a half-life of about 5700 years, and can be abundantly present in the upper atmosphere by nuclear reactions involving cosmic rays and ordinary nitrogen ( 14 N).

[0037] Fossil fuels produce radioactive carbon isotopes that decay over a long period of time. 14 The ratio of carbon (C) can be virtually zero. When bio-derived materials are used as raw materials for 3-hydroxypropionic acid, or when fossil fuels are used in combination with them, the content of radiocarbon isotopes (pMC) and biocarbon in the 3-hydroxypropionic acid can be measured according to the ASTM D6866-21 standard.

[0038] For example, the measurement method involves measuring the carbon atoms contained in the target compound in the form of graphite or carbon dioxide gas using a mass spectrometer, or by liquid flash spectroscopy. 14 C ions 12 An accelerator may be used to separate the C ions, or the two isotopes can be separated and their content and content ratio measured using a mass spectrometer.

[0039] The cosmetic composition can suppress the generation of reactive nitrogen species, which are inflammation mediators, through the action of the active ingredient. As a result, the cosmetic composition can exhibit excellent anti-inflammatory effects, such as preventing or improving symptoms caused by intracellular inflammation.

[0040] Here, the active nitrogen species are nitric oxide (NO), nitrate (NO3) - ), nitrite (NO2 - ), nitrate peroxide (ONOO - It is one or more compounds selected from the group consisting of ), and 3-nitrotyrosine.

[0041] According to one embodiment, the cosmetic composition may contain the active ingredient in an amount of 0.01% to 1.5% by weight, based on the total weight of the composition.

[0042] Specifically, the cosmetic composition may contain the active ingredient in an amount of 0.01% or more by weight, or 0.012% or more by weight, and 1.5% or less by weight, or 1.25% or less by weight, or 1.1% or less by weight, or 1.0% or less by weight, based on the total weight of the cosmetic composition.

[0043] In order to ensure that an anti-inflammatory effect is sufficiently achieved by the action of the active ingredient, the cosmetic composition preferably contains 0.01% or more by weight of the active ingredient, or 0.012% or more by weight of the active ingredient.

[0044] However, if the active ingredient is present in excess, the anti-inflammatory effect may decrease, or side effects such as cytotoxicity may occur. For this reason, it is preferable that the cosmetic composition contains the active ingredient in an amount of 1.5% by weight or less, or 1.25% by weight or less, or 1.1% by weight or less, or 1.0% by weight or less.

[0045] Preferably, the cosmetic composition may contain the active ingredient in an amount of 0.01% to 1.5% by weight, or 0.01% to 1.25% by weight, or 0.01% to 1.1% by weight, or 0.01% to 1.0% by weight, or 0.012% to 1.0% by weight, based on the total weight of the cosmetic composition.

[0046] According to one embodiment, the cosmetic composition may have a common cosmetic dosage form in the art to which the present invention belongs. For example, the cosmetic composition may have a dosage form such as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, oil, foam, pack, spray, aerosol, balm, solid soap, liquid soap, powder foundation, emulsion foundation, or wax foundation.

[0047] According to one embodiment, the cosmetic composition may contain, in addition to the active ingredient, organic solvents, fatty substances, solvents, concentrates, gelling agents, softening agents, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, emulsifiers, fillers, chelating agents, preservatives, vitamins, wetting agents, dyes, pigments, hydrophilic or lipophilic surfactants, and the like. Furthermore, the cosmetic composition may contain auxiliary agents commonly used in the fields of cosmetic science or dermatology.

[0048] The cosmetic composition may further include a physiologically acceptable medium, which is composed of water or a mixture of an organic solvent and water.

[0049] As an example, the organic solvent can be a C1-C4 lower alcohol such as acetone, ethanol, and isopropyl alcohol; an alkylene glycol such as ethylene glycol and propylene glycol; ethylene glycol monomethyl ether, monoethyl ether, monobutyl ether, or propylene glycol. The physiologically acceptable medium may be applied in an amount of 1 to 90% by weight relative to the total weight of the cosmetic composition.

[0050] The medium can be thickened using a thickening agent commonly used in cosmetics or pharmaceuticals. The thickening agent may be applied in an amount of 0.1 to 5% by weight relative to the total weight of the composition.

[0051] Furthermore, depending on the various embodiments of the cosmetic composition, an ordinary technician can select the auxiliary agents commonly required to manufacture such a composition. As an example, the auxiliary agents that can be used include preservatives, stabilizers, pH adjusters, osmotic pressure modifiers, emulsifying agents, light-blocking agents, antioxidants, fragrances, dyes, anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants. According to one embodiment, when the dosage form of the cosmetic composition is a powder or a spray, it may contain carrier components such as lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder.

[0052] According to one embodiment, if the dosage form of the cosmetic composition is a paste, gel, or cream, it may contain carrier components such as animal oils, vegetable oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicones, bentonite, silica, talc, and zinc oxide.

[0053] According to one embodiment, when the dosage form of the cosmetic composition is a solution or emulsion, it may contain carrier components such as a solvent, solubilizer, or emulsifier. For example, the solution or emulsion dosage form can include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0054] According to one embodiment, when the dosage form of the cosmetic composition is a suspension, liquid diluents such as water, ethanol, or propylene glycol; suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; and microcrystalline cellulose, aluminum methhydroxyl, bentonite, etc. can be used.

[0055] According to one example, if the dosage form of the cosmetic composition is a cleanser containing a surfactant, it may contain carrier components such as aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinate monoester, isethionate, imidazolinium derivative, sodium methyl cocoyl taurate, sodium lauroyl sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, and ethoxylated glycerol fatty acid ester.

[0056] According to another embodiment of the invention, uses of 3-hydroxypropionic acid or its derivatives for the manufacture of anti-inflammatory cosmetics are provided.

[0057] Preferably, uses of 3-hydroxypropionic acid or its derivatives for the production of the anti-inflammatory cosmetic compositions described above are provided.

[0058] 3-hydroxypropionic acid has the effect of suppressing the production of reactive nitrogen species, which are inflammation mediators involved in inducing inflammation within cells. Cosmetic compositions containing 3-hydroxypropionic acid or its derivatives as an active ingredient can be used for anti-inflammatory purposes.

[0059] In the above-mentioned applications, the active ingredient, 3-hydroxypropionic acid or its derivative, may be used in an amount of 0.01% to 1.5% by weight based on the total weight of the cosmetic composition.

[0060] In order to ensure that the anti-inflammatory effect is sufficiently achieved by the action of the active ingredient, it is preferable that the active ingredient be used in an amount of 0.01% by weight or more, or 0.012% by weight or more, based on the total weight of the cosmetic composition. However, if the active ingredient is used in excess, the anti-inflammatory effect may decrease, or side effects such as cytotoxicity may occur. For this reason, it is preferable that the active ingredient be used in an amount of 1.5% by weight or less, or 1.25% by weight or less, or 1.1% by weight or less, or 1.0% by weight or less, based on the total weight of the cosmetic composition. Preferably, the active ingredient may be used in an amount of 0.01% to 1.5% by weight, or 0.01% to 1.25% by weight, or 0.01% to 1.1% by weight, or 0.01% to 1.0% by weight, or 0.012% to 1.0% by weight, based on the total weight of the cosmetic composition.

[0061] According to yet another embodiment of the invention, a method is provided for suppressing the generation of reactive nitrogen species, which are mediators of inflammation, using a cosmetic composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0062] Preferably, the method for suppressing the generation of the reactive nitrogen species may be carried out using the anti-inflammatory cosmetic composition described above. The method may be carried out by applying the cosmetic composition to a part of the human body where anti-inflammatory treatment is required. The method may be carried out for a period of 1 to 6 months, 1 to 7 days a week, and 1 to several times a day (for example, 1 to 5 times or 1 to 3 times).

[0063] According to yet another embodiment of the invention, an anti-inflammatory pharmaceutical composition is provided comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0064] As a result of our continued research, we have confirmed that 3-hydroxypropionic acid can exhibit excellent anti-inflammatory effects, such as preventing, treating, or improving symptoms caused by intracellular inflammation.

[0065] In particular, 3-hydroxypropionic acid suppresses the production of reactive nitrogen species, which are inflammation mediators involved in inducing inflammation within cells, thereby enabling pharmaceutical compositions containing 3-hydroxypropionic acid or its derivatives as active ingredients to exhibit excellent anti-inflammatory effects. The anti-inflammatory pharmaceutical composition contains 3-hydroxypropionic acid or a derivative thereof as an active ingredient. Preferably, the anti-inflammatory pharmaceutical composition contains 3-hydroxypropionic acid as an active ingredient.

[0066] 3-hydroxypropionic acid can be used as an active ingredient if it is synthesized by chemical or biological methods.

[0067] According to one embodiment, 3-hydroxypropionic acid obtained by a biological process such as fermenting a bacterial strain capable of producing 3-hydroxypropionic acid can preferably be used as the active ingredient. The 3-hydroxypropionic acid obtained by the above method is a radioactive carbon isotope ( 14 C) May include.

[0068] Preferably, the active ingredient may have a radioactive carbon isotope content of 20 pMC (percent modern carbon) or more as measured according to ASTM D6866-21, and a biocarbon content of 20% by weight or more. Specifically, the active ingredient may have a radioactive carbon isotope content of 20 pMC or more, or 50 pMC or more, or 90 pMC or more, or 100 pMC or more, or 90-110 pMC as measured according to ASTM D6866-21; and a biocarbon content of 20% by weight or more, or 50% by weight or more, or 80% by weight or more, or 90% by weight or more, or 95% by weight or more, or 90-100% by weight.

[0069] The aforementioned pharmaceutical composition can suppress the generation of reactive nitrogen species, which are inflammation mediators, through the action of the active ingredient. As a result, the pharmaceutical composition can exhibit excellent anti-inflammatory effects, such as preventing, treating, or improving symptoms caused by intracellular inflammation.

[0070] Here, the active nitrogen species are nitric oxide (NO), nitrate (NO3) - ), nitrite (NO2 - ), nitrate peroxide (ONOO - It is one or more compounds selected from the group consisting of ), and 3-nitrotyrosine.

[0071] According to one embodiment, the pharmaceutical composition may contain the active ingredient in an amount of 0.01% to 1.5% by weight, based on the total weight of the pharmaceutical composition.

[0072] Specifically, the pharmaceutical composition may contain the active ingredient in an amount of 0.01% or more by weight, or 0.012% or more by weight, and 1.5% or less by weight, or 1.25% or less by weight, or 1.1% or less by weight, or 1.0% or less by weight, based on the total weight of the pharmaceutical composition.

[0073] In order to ensure that an anti-inflammatory effect is sufficiently achieved by the action of the active ingredient, the pharmaceutical composition preferably contains 0.01% or more by weight of the active ingredient, or 0.012% or more by weight of the active ingredient.

[0074] However, if the active ingredient is present in excess, the anti-inflammatory effect may decrease, or side effects such as cytotoxicity may occur. For this reason, it is preferable that the pharmaceutical composition contains the active ingredient in an amount of 1.5% by weight or less, or 1.25% by weight or less, or 1.1% by weight or less, or 1.0% by weight or less.

[0075] Preferably, the pharmaceutical composition may contain the active ingredient in an amount of 0.01% to 1.5% by weight, or 0.01% to 1.25% by weight, or 0.01% to 1.1% by weight, or 0.01% to 1.0% by weight, or 0.012% to 1.0% by weight, based on the total weight of the pharmaceutical composition.

[0076] The aforementioned pharmaceutical composition may further contain a pharmaceutically acceptable carrier.

[0077] The carrier can be any material commonly used in the formulation of pharmaceutical compositions, without any special limitations. For example, the carrier may be sucrose, sorbitol, mannitol, lactose, dextrose, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, propyl 4-hydroxybenzoate, talc, magnesium stearate, mineral oil, etc. Pharmaceutically acceptable carriers and formulations are described in detail in Remington's The Science and Practice of Pharmacy (23rd Edition, 2020).

[0078] The pharmaceutical composition may be administered orally or parenterally. When administered parenterally, methods such as topical application, subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, and transdermal administration are applicable.

[0079] The appropriate dosage of the pharmaceutical composition can be determined by comprehensively considering factors such as the patient's age, weight, sex, formulation method, administration method, and administration time.

[0080] The pharmaceutical composition may be formulated by applying pharmaceutically acceptable carriers and / or excipients. The dosage form of the pharmaceutical composition may be a solution in an aqueous medium or oil, a suspension, an emulsion, an ointment, a powder, granules, a tablet, or a capsule.

[0081] According to yet another embodiment of the invention, uses of 3-hydroxypropionic acid or its derivatives for the manufacture of anti-inflammatory agents are provided.

[0082] Preferably, uses of 3-hydroxypropionic acid or its derivatives for the production of the anti-inflammatory pharmaceutical compositions described above are provided.

[0083] 3-hydroxypropionic acid has the effect of suppressing the production of reactive nitrogen species, which are inflammation mediators involved in inducing inflammation within cells. Pharmaceutical compositions containing 3-hydroxypropionic acid or its derivatives as an active ingredient can be used for anti-inflammatory purposes.

[0084] In the above-mentioned applications, the active ingredient, 3-hydroxypropionic acid or its derivative, may be used in an amount of 0.01% to 1.5% by weight based on the total weight of the pharmaceutical composition.

[0085] In order to ensure that the anti-inflammatory effect is sufficiently achieved by the action of the active ingredient, it is preferable that the active ingredient be used in an amount of 0.01% by weight or more, or 0.012% by weight or more, based on the total weight of the pharmaceutical composition. However, if the active ingredient is used in excess, the anti-inflammatory effect may decrease, or side effects such as cytotoxicity may occur. Therefore, it is preferable that the active ingredient be used in an amount of 1.5% by weight or less, or 1.25% by weight or less, or 1.1% by weight or less, or 1.0% by weight or less, based on the total weight of the pharmaceutical composition. Preferably, the active ingredient may be used in an amount of 0.01% to 1.5% by weight, or 0.01% to 1.25% by weight, or 0.01% to 1.1% by weight, or 0.01% to 1.0% by weight, or 0.012% to 1.0% by weight, based on the total weight of the pharmaceutical composition.

[0086] According to yet another embodiment of the invention, a method is provided for suppressing the generation of reactive nitrogen species, which are mediators of inflammation, using a pharmaceutical composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

[0087] Preferably, the method for suppressing the generation of the reactive nitrogen species may be carried out using the anti-inflammatory pharmaceutical composition described above. The method may be carried out orally or parenterally. The method may be administered for a period of 1 to 6 months, 1 to 7 days a week, once to several times a day (for example, once to 5 times or once to 3 times). The method may be carried out by a standard procedure, taking into account factors such as the patient's age, weight, sex, dosage form of 3-hydroxypropionic acid or its derivatives, method of administration, and timing of administration. [Effects of the Invention]

[0088] The present invention provides cosmetic compositions and pharmaceutical compositions that can suppress the production of reactive nitrogen species, which are inflammation mediators involved in inducing inflammation within cells. [Modes for carrying out the invention]

[0089] The function and effects of the invention will be explained in more detail below through specific embodiments of the invention. However, these are presented as examples for understanding the invention. It is not intended that the scope of the invention's rights be limited in any sense through the following embodiments, and it will be obvious to a person of the skill that various changes and modifications are possible within the scope of the invention and its technical concept.

[0090] Manufacturing Example 1 Recombinant vectors were prepared by introducing genes encoding glycerol dehydratase and aldehyde dehydrogenase, which are known to produce 3-hydroxypropionic acid using glycerol as a substrate. These recombinant vectors were introduced into E. coli W3110 strain to create a strain for 3-hydroxypropionic acid production.

[0091] Specifically, the BtuR gene encoding adenosyltransferase was cloned into a plasmid pCDF containing the genes encoding glycerol dehydridase (dhaB), aldehyde dehydrogenase (aldH), and glycerol dehydratase reactivase (gdrAB) to obtain the pCDF_J23101_dhaB_gdrAB_J23100_aldH_btuR vector. This vector was introduced into the W3110 strain (KCCM40219) using electroporation with an electroporation device (Bio-Rad, Gene Pulser Xcell) to create a strain for 3-hydroxypropionic acid production.

[0092] The aforementioned 3-hydroxypropionic acid production strain was fermented in a 5L fermenter at 35°C using unpurified glycerol as a carbon source to produce 3-hydroxypropionic acid. To prevent a decrease in pH due to the production of 3-hydroxypropionic acid, calcium hydroxide (Ca(OH)2), an alkali metal salt, was added to maintain a neutral pH during fermentation.

[0093] After fermentation culture, cells were removed by centrifugation (4000 rpm, 10 minutes, 4°C), and primary purification was carried out using activated carbon. The concentration of 3-hydroxypropionic acid in the fermentation liquid after the primary purification was at the level of 50-100 g / L, and it was concentrated to 600 g / L using a rotary evaporator (50°C, 50 mbar), and Ca(3HP)2 crystals were produced by stirring at room temperature (300 rpm).

[0094] The crystals were washed three times with ethanol, dried in an oven at 50°C, and finally recovered. The weight of the crystals was measured, and the crystals were dissolved in water to obtain 3-hydroxypropionic acid (3HP) using high-performance liquid chromatography (HPLC).

[0095] Manufacturing Example 2 3-hydroxypropionic acid (3HP) was obtained by a method substantially the same as in Production Example 1, except that Mg(OH)2 was used instead of Ca(OH)2 as the alkali metal salt.

[0096] Example 1 A lotion was prepared by mixing 0.0125% by weight of 3-hydroxypropionic acid obtained in Production Example 1, 0.5% by weight of hydroxyethylcellulose, 2% by weight of cetostearyl alcohol, 2% by weight of stearyltriethylammonium chloride, and the remaining purified water (total 100% by weight).

[0097] Example 2 A lotion was prepared by mixing 0.025% by weight of 3-hydroxypropionic acid obtained in Production Example 1, 0.5% by weight of hydroxyethylcellulose, 2% by weight of cetostearyl alcohol, 2% by weight of stearyltriethylammonium chloride, and the remaining purified water (total 100% by weight).

[0098] Example 3 A toner emulsion was prepared by mixing 0.05% by weight of 3-hydroxypropionic acid obtained in Production Example 1, 55% by weight of ethanol, 3% by weight of glycerin, 5% by weight of castor oil, and the remaining purified water (total 100% by weight).

[0099] Example 4 A toner emulsion was prepared by mixing 0.1% by weight of 3-hydroxypropionic acid obtained in Production Example 1, 55% by weight of ethanol, 3% by weight of glycerin, 5% by weight of castor oil, and the remaining purified water (total 100% by weight).

[0100] Example 5 A pharmaceutical composition in the form of an ointment was prepared by mixing 0.0125% by weight of 3-hydroxypropionic acid obtained in Production Example 1, 0.5% by weight of hydroxyethylcellulose, 2% by weight of cetostearyl alcohol, 2% by weight of stearyltriethylammonium chloride, and the remainder of purified water (total 100% by weight).

[0101] Example 6 A pharmaceutical composition in the form of an ointment was prepared by mixing 0.025% by weight of 3-hydroxypropionic acid, 0.5% by weight of hydroxyethylcellulose, 2% by weight of cetostearyl alcohol, 2% by weight of stearyltriethylammonium chloride, and the remaining amount of purified water (total 100% by weight) obtained in Production Example 1.

[0102] Example 7 A pharmaceutical composition in the form of an emulsion was prepared by mixing 0.05% by weight of 3-hydroxypropionic acid obtained in Production Example 1, 55% by weight of ethanol, 3% by weight of glycerin, 5% by weight of castor oil, and the remaining amount of purified water (total 100% by weight).

[0103] Example 8 A pharmaceutical composition in the form of an emulsion was prepared by mixing 0.1% by weight of 3-hydroxypropionic acid obtained in Production Example 1, 55% by weight of ethanol, 3% by weight of glycerin, 5% by weight of castor oil, and the remainder of purified water (total 100% by weight).

[0104] Experimental Example 1 (Measurement of radioactive carbon isotope and biocarbon content) The radiocarbon isotope content (pMC) and biocarbon content of 3-hydroxypropionic acid obtained in Production Examples 1 and 2 were measured using ASTM D6866-21 (Method B).

[0105] The biocarbon content refers to the biocarbon content contained in the 3-hydroxypropionate crystals obtained in Production Examples 1 and 2, and the ratio of radiocarbon isotopes (pMC) refers to the radiocarbon isotopes contained in the 3-hydroxypropionate crystals. 14 C) and radioactive carbon isotopes of modern reference materials ( 14 This refers to the ratio of C). [Table 1]

[0106] Referring to Table 1 above, it was confirmed that both the 3HP salt crystals of production examples 1 and 2 had a radioactive carbon isotope ratio of 10¹ pMC or higher and a biocarbon content of 100% by weight.

[0107] Experimental Example 2 (Evaluation of the ability to suppress reactive nitrogen species) Mouse macrophages were placed in a 6-well plate at a rate of 1 × 10⁶ 6 After culturing the cultures individually for 24 hours, they were treated with an LPS (Lipopolysaccharide, concentration 1 μg / ml) solution, and then with four concentrations of 3-hydroxypropionic acid aqueous solution (3HP concentrations 0 wt%, 0.0125 wt%, 0.025 wt%, and 0.05 wt%) according to Production Example 1, followed by another 24 hours of cultivation. Subsequently, only the culture medium was separated and the supernatant was collected by centrifugation for 10 minutes. The supernatant was mixed with Gries' reagent (Sigma-Aldrich) in a 1:1 ratio and reacted at room temperature, after which the absorbance (OD, wavelength 540 nm) was measured using a microplate reader. The measured values ​​were substituted into a regression equation obtained from a standard curve created by reacting Gries' reagent (Sigma-Aldrich) with NaNO2 in a 1:1 ratio to calculate the amount of nitric oxide (NO) produced. Here, a negative control group was used in which neither the LPS solution nor the 3HP aqueous solution was treated. [Table 2]

[0108] Based on the experimental results described above, it was confirmed that 3-hydroxypropionic acid exhibits an effect of suppressing the generation of reactive nitrogen species at the aforementioned treatment concentration.

[0109] Dosage Form Example 1 A softening lotion (skin lotion) is prepared by mixing 0.2% by weight of 3-hydroxypropionic acid according to the above-mentioned Production Example 1, 3.0% by weight of glycerin, 2.0% by weight of butylene glycol, 2.0% by weight of propylene glycol, 0.1% by weight of polyacrylic acid, 0.2% by weight of polyethylene glycol-12 nonylphenyl ether, 0.4% by weight of polysorbate-80, 10.0% by weight of ethanol, 0.1% by weight of triethanolamine, and the remainder of purified water.

[0110] Dosage Form Example 2 A nourishing lotion (milk lotion) is prepared by mixing 1.0% by weight of 3-hydroxypropionic acid according to the above-mentioned Production Example 1, 3.0% by weight of glycerin, 3.0% by weight of butylene glycol, 0.5% by weight of liquid paraffin, 4.0% by weight of beeswax, 5.0% by weight of caprylic / capric triglyceride, 5.0% by weight of squalene, 1.5% by weight of polysorbate-60, 1.0% by weight of cetearyl alcohol, 1.5% by weight of sorbitan sesquioleate, 0.1% by weight of polyacrylic acid, 0.2% by weight of triethanolamine, and the remainder of purified water.

[0111] Dosage Form Example 3 A nourishing cream is prepared by mixing 2.0% by weight of 3-hydroxypropionic acid according to the above-mentioned Production Example 1, 3.0% by weight of glycerin, 3.0% by weight of butylene glycol, 7.0% by weight of liquid paraffin, 7.0% by weight of beta-glucan, 3.0% by weight of caprylic / capric triglyceride, 5.0% by weight of squalene, 1.5% by weight of cetearyl glucoside, 1.2% by weight of polysorbate-60, 0.4% by weight of sorbitan stearate, 0.1% by weight of polyacrylic acid, 0.1% by weight of triethanolamine, and the remainder of purified water.

[0112] Dosage Form Example 4 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 200 mg of lactose, and 200 mg of galactooligosaccharide are mixed according to the above production example 1, granulated using a fluid bed dryer, and then 5 mg of sugar ester is added to produce a tablet composition. 500 mg of the tablet composition is compressed into tablets to produce tablets.

[0113] Dosage Form Example 5 A soft capsule filling solution is prepared by mixing 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 10 mg of hydrogenated vegetable oil, and 9 mg of lecithin according to the above-mentioned Production Example 1. Separately, a soft capsule sheet is prepared by mixing gelatin (65% by weight), glycerin (25% by weight), and sorbitol solution (10% by weight). Soft capsules are prepared by filling each capsule with 400 mg of the soft capsule filling solution.

[0114] Dosage Form Example 6 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 500 mg of starch, and 200 mg of anhydrous crystalline glucose are mixed according to the above-mentioned Production Example 1, formed into granules using a fluid bed granulator, and then filled into packets to produce a granular preparation.

[0115] Dosage Form Example 7 After mixing 8 mg of 3-hydroxypropionic acid, 9 mg of vitamin C, 9 mg of vitamin E, 0.7 g of citric acid, 10 g of glucose, and 25 g of liquid oligosaccharide according to the above production example 1, 300 ml of purified water is added to produce a drinkable composition. The drinkable composition is filled into bottles in 200 ml portions and sterilized at 130°C for approximately 5 seconds to produce a drinkable product.

[0116] Dosage Form Example 8 A solution is prepared by mixing 30 mg of 3-hydroxypropionic acid according to the above-mentioned Production Example 1, an appropriate amount of sterile distilled water for injection, and an appropriate amount of pH adjuster.

[0117] Although the present invention has been described above, even if only by limited embodiments, the present invention is not limited thereto, and of course, a wide range of modifications and variations are possible by persons with ordinary skill in the art to which the present invention pertains, within the equivalent scope of the technical concept of the present invention and the claims described below.

Claims

1. An anti-inflammatory cosmetic composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

2. The cosmetic composition is an anti-inflammatory cosmetic composition according to claim 1, which suppresses the generation of reactive nitrogen species.

3. The anti-inflammatory cosmetic composition according to claim 1, wherein the cosmetic composition contains 0.01% to 1% by weight of the active ingredient based on the total weight of the composition.

4. The anti-inflammatory cosmetic composition according to claim 1, wherein the active ingredient has a radioactive carbon isotope content of 20 pMC (percent modern carbon) or more as measured by ASTM D6866-21 standard, and a biocarbon content of 20% by weight or more.

5. The anti-inflammatory cosmetic composition according to claim 1, further comprising a physiologically acceptable medium.

6. The anti-inflammatory cosmetic composition according to claim 1, wherein the cosmetic composition has a dosage form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, oil, foam, pack, spray, aerosol, balm, solid soap, liquid soap, powder foundation, emulsion foundation, or wax foundation.

7. An anti-inflammatory pharmaceutical composition comprising 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

8. The pharmaceutical composition is an anti-inflammatory pharmaceutical composition according to claim 7, wherein the pharmaceutical composition suppresses the generation of reactive nitrogen species.

9. The anti-inflammatory pharmaceutical composition according to claim 7, wherein the pharmaceutical composition contains 0.01% to 1% by weight of the active ingredient based on the total weight of the composition.

10. The anti-inflammatory pharmaceutical composition according to claim 7, wherein the active ingredient has a radioactive carbon isotope content of 20 pMC (percent modern carbon) or more as measured by ASTM D6866-21 standard, and a biocarbon content of 20% by weight or more.

11. The anti-inflammatory pharmaceutical composition according to claim 7, further comprising a pharmaceutically acceptable carrier.

12. The anti-inflammatory pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is for oral or parenteral use.

13. Uses of 3-hydroxypropionic acid or its derivatives for the manufacture of anti-inflammatory cosmetics or anti-inflammatory drugs.

14. A method for suppressing the generation of reactive nitrogen species, which are mediators of inflammation, using a cosmetic composition or pharmaceutical composition containing 3-hydroxypropionic acid or a derivative thereof as an active ingredient.

Images